Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 1;1(6):957-958.
doi: 10.4161/onci.19974.

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody

Roch Houot  1 , Holbrook Kohrt, Ron Levy
Affiliations

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody

Roch Houot et al. Oncoimmunology. .

Abstract

Monoclonal antibodies (mAb) induce tumor regression through antibody-dependant cellular cytotoxicity (ADCC). We recently showed that an agonistic anti-CD137 mAb stimulates natural killer (NK) cells which have been activated by a tumor-specific mAb, resulting in increased ADCC against cancer cells.

PubMed Disclaimer

Figures

None
Figure 1. Cooperation for tumor cell killing between a tumor-specific mAb and an anti-CD137 stimulatory mAb. (A) A mAb directed against a tumor cell target binds to the cancer cell. (B) The tumor-directed mAb then recruits NK effector cells through their Fc receptor. (C) Binding of the tumor-directed mAb to the FcR activates NK cells which results in degranulation and upregulation of CD137 on their surface. (D) Addition of an agonistic anti-CD137 mAb further activates NK cells and increases their cytotoxicity against tumor cells.
See this image and copyright information in PMC

References

    1. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–6. doi: 10.1038/74704. - DOI - PubMed
    1. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789–96. doi: 10.1200/JCO.2007.14.8957. - DOI - PubMed
    1. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–7. doi: 10.1200/JCO.2003.05.013. - DOI - PubMed
    1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317–27. - PMC - PubMed
    1. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117:2423–32. doi: 10.1182/blood-2010-08-301945. - DOI - PMC - PubMed